Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Top 5 Top of the line Books of the Year - 2Israel has clear objectives south of Litani River, but will face difficult choices further north
- 3UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- 4'All Her Fault' ending explained: The shocking conclusion to the psychological thriller inspired by true events
- 5Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- The Main 20 Gaming Control center Ever
- Step by step instructions to Pick A Pre-owned vehicle Stage
- Inconceivable Spots To Stargaze All over The Planet
- 4 Home Rec center Hardware Decisions for Little Spaces
- Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
- Moscow: Russia well-positioned to withstand oil market shocks
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
- Boats escort freed whale away from shallow waters off German coast
